Table 2. Baseline characteristics of the study patients.
| Variable | FCM group (n = 35) | Non-FCM group (n = 30) | p value |
| Demographics | |||
| Age, years, mean ± SD | 53 ± 11 | 56 ± 10 | 0.135 |
| Female sex, n (%) | 14 (40) | 13 (43) | 0.786 |
| Physical findings | |||
| Body surface area (m2) | 1.72 ± 0.10 | 1.76 ± 0.08 | 0.188 |
| Body mass index (kg/m2) | 23.8 ± 2.7 | 23.9 ± 2.1 | 0.827 |
| Systolic blood pressure, mmHg | 119 ± 14 | 113 ± 24 | 0.503 |
| Medical history, n (%) | |||
| Hypertension | 11 (31) | 9 (30) | 0.901 |
| Diabetes mellitus | 12 (34) | 9 (30) | 0.713 |
| COPD | 9 (26) | 8 (27) | 0.931 |
| Smoking | 12 (34) | 7 (23) | 0.333 |
| Atrial fibrillation | 3 (9) | 2 (7) | 0.774 |
| Heart failure etiology | |||
| Ischaemic, n (%) | 22 (63) | 19 (63) | 0.968 |
| Functional status, n (%) | |||
| NYHA class II | 15 (43) | 19 (63) | 0.099 |
| NYHA class III | 20 (57) | 11 (37) | 0.099 |
| Baseline LVEF, % | 31 ± 4 | 31 ± 3 | 0.853 |
| Baseline LVEDD, mm | 65 ± 8 | 64 ± 8 | 0.747 |
| Baseline LVESD, mm | 56 ± 8 | 55 ± 8 | 0.772 |
| Baseline LVESV, mL | 165 ± 58 | 167 ± 58 | 0.885 |
| Baseline LVEDV, mL | 234 ± 67 | 234 ± 65 | 0.974 |
| Baseline QRS duration, ms | 148.4 ± 5.3 | 149.8 ± 5.0 | 0.363 |
| Laboratory data | |||
| Hemoglobin, g/dL | 9.9 ± 0.7 | 10.3 ± 0.7 | 0.055 |
| Ferritin, μg/L | 10.7 ± 5.0 | 13.5 ± 3.9 | 0.012 |
| eGFR, mL/min/1.73 m2 | 65 ± 10 | 67 ± 11 | 0.623 |
| C-reactive protein, mg/L | 2.97 ± 0.60 | 2.82 ± 0.64 | 0.387 |
| Heart failure medications, n (%) | |||
| ACEi/ARB/ARNi | 26 (74) | 22 (73) | 0.931 |
| ARNi | 4 (11) | 3 (10) | 0.853 |
| Spironolactone/eplerenone | 24 (67) | 22 (73) | 0.674 |
| Beta-blocker | 28 (80) | 24 (80) | 1.000 |
| Loop diuretics | 22 (63) | 21 (70) | 0.544 |
| Ivabradine | 15 (43) | 14 (47) | 0.758 |
Values are given as mean ± standard deviation or n (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; NYHA, New York Heart Association; SD, standard deviation.